2017 Radford Performance-Based Equity Study - US Life Sciences

Explore the current state of performance shares in the US life sciences market


With the adoption of performance-based stock awards in long-term incentive plans continually increasing among life sciences companies, more and more organzations continue to seek out ways to make these programs more effective. However, performance-based equity programs are not static and there has been substantial changes in practices over time. 

To that end, this study examines how performance share plan design has shifted as prevalence has grown among 62 leading US biotech and pharmaceutical companies.

The cost to purchase this study is $750.

    Buy Now          Learn More  

What's covered in this study?

The 2017 Radford Performance-Based Equity Report for US Life Sciences Companies explores the current state of performance shares in the US life sciences market, including prevalence and equity mix, plan design and the alignment of pay with performance. Full contents include: 

Section 1: Introduction

  • About this Study

Section 2: Prevalence of Performance-Based Equity Plans
& Equity Mix

  • More Companies Adopt Performance-Based Equity Plans
  • Performance Shares Account for Larger Portion of Equity Vehicle Mix
  • Value Delivered for Different Equity Vehicles

Section 3: Plan Design

  • Operating vs. Market Metrics
  • Minimum and Maximum Payout Thresholds
  • Length of Performance-Based Equity Periods

Section 4: Alignment of Pay to Performance

  • Measuring the Effectiveness of TSR-Based Plans

Images shown are for illustrative purposes only and may not reflect actual data.

Who participated in the study?

The US Life Sciences Edition of this study includes data from 62 companies, including: 

  • AbbVie
  • ACADIA Pharmaceuticals 
  • Acorda Therapeutics
  • Akorn
  • Alexion Pharmaceuticals
  • Alkermes
  • AMAG Pharmaceuticals
  • Amgen
  • Biogen
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb Company
  • Catalent
  • Celgene 
  • Clovis Oncology
  • Depomed
  • Eagle Pharmaceuticals
  • Eli Lilly and Company
  • Emergent BioSolutions
  • Endo
  • Exact Sciences 
  • Exelixis
  • Genomic Health
  • Gilead Sciences
  • Halozyme Therapeutics
  • Heron Therapeutics
  • Horizon Pharma
  • Impax Laboratories
  • Incyte
  • Innoviva
  • INSYS Therapeutics
  • Intercept Pharmaceuticals
  • Ionis Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Lannett Company
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • Merck & Co.
  • Merrimack Pharmaceuticals
  • MiMedx Group
  • Momenta Pharmaceuticals
  • Myriad Genetics
  • Nektar Therapeutics
  • Neurocrine Biosciences
  • Opko Health
  • Pacira Pharmaceuticals
  • Perrigo Company plc
  • Pfizer
  • Prestige Brands Holdings
  • Radius Health
  • Regeneron Pharmaceuticals
  • Repligen Corporation
  • Retrophin
  • Sarepta Therapeutics
  • Seattle Genetics
  • Supernus Pharmaceuticals
  • Synergy Pharmaceuticals 
  • Tesaro
  • The Medicines Company
  • United Therapeutics
  • Vertex Pharmaceuticals

Report Pricing

The 2017 Radford Performance-Based Equity Study - US Life Sciences Companies Edition can be purchased via credit card for $750.